Liu Xinkui, Wu Jiarui, Zhang Dan, Wang Kaihuan, Duan Xiaojiao, Meng Ziqi, Zhang Xiaomeng
Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, China.
Evid Based Complement Alternat Med. 2018 May 2;2018:7802639. doi: 10.1155/2018/7802639. eCollection 2018.
Willd. (HDW) is one of the renowned herbs often used in the treatment of gastric cancer (GC). However, its curative mechanism has not been fully elucidated.
To systematically investigate the mechanisms of HDW in GC.
A network pharmacology approach mainly comprising target prediction, network construction, and module analysis was adopted in this study.
A total of 353 targets of the 32 bioactive compounds in HDW were obtained. The network analysis showed that CA isoenzymes, p53, PIK3CA, CDK2, P27, cyclin D1, cyclin B1, cyclin A2, AKT1, BCL2, MAPK1, and VEGFA were identified as key targets of HDW in the treatment of GC. The functional enrichment analysis indicated that HDW probably produced the therapeutic effects against GC by synergistically regulating many biological pathways, such as nucleotide excision repair, apoptosis, cell cycle, PI3K/AKT/mTOR signaling pathway, VEGF signaling pathway, and Ras signaling pathway.
This study holistically illuminates the fact that the pharmacological mechanisms of HDW in GC might be strongly associated with its synergic modulation of apoptosis, cell cycle, differentiation, proliferation, migration, invasion, and angiogenesis.
威灵仙（HDW）是常用于治疗胃癌（GC）的著名草药之一。然而，其治疗机制尚未完全阐明。
系统研究HDW治疗GC的机制。
本研究采用了一种主要包括靶点预测、网络构建和模块分析的网络药理学方法。
获得了HDW中32种生物活性化合物的353个靶点。网络分析表明，CA同工酶、p53、PIK3CA、CDK2、P27、细胞周期蛋白D1、细胞周期蛋白B1、细胞周期蛋白A2、AKT1、BCL2、MAPK1和VEGFA被确定为HDW治疗GC的关键靶点。功能富集分析表明，HDW可能通过协同调节多种生物学途径，如核苷酸切除修复、凋亡、细胞周期、PI3K/AKT/mTOR信号通路、VEGF信号通路和Ras信号通路，对GC产生治疗作用。
本研究全面阐明了HDW治疗GC的药理机制可能与其对凋亡、细胞周期、分化、增殖、迁移、侵袭和血管生成的协同调节密切相关。
